#Vienna #Austria #vaccine #Elaris #Valneva

Elaris FlexCo Secures Licensing Agreement for C. difficile Vaccine

Elaris FlexCo, a pioneering biotechnology company based in Austria, is making significant strides in combating serious bacterial infections with its new partnership with Valneva SE. This collaboration, announced on March 18, 2026, marks a crucial step forward in addressing the pressing public health challenge posed by Clostridioides difficile (C. difficile), which is associated with high rates of morbidity and mortality in hospitals and long-term care facilities.

Under the terms of the exclusive global license agreement, Elaris gains access to Valneva's advanced antigen technology specifically aimed at developing a vaccine candidate, known as VLA84, for C. difficile. This makes Elaris one of the first companies to have the opportunity to leverage Valneva's cutting-edge technology to create a role-based vaccine that may significantly enhance immune responses against the infection.

Jason Golan, Chief Executive Officer and Co-Founder of Elaris, stated, "Securing this license represents an important step toward our goal of preventing serious bacterial infections that disproportionately affect aging and vulnerable populations." This comes at a time when C. difficile continues to be a major concern in healthcare settings, with rising rates of hospital-acquired infections reported worldwide. In the U.S. alone, nearly 500,000 infections are recorded annually, leading to approximately 29,000 deaths. In Europe, more than 170,000 healthcare-associated infections are linked to C. difficile each year. The agreement highlights Elaris' commitment to not only developing its lead vaccine program but also enhancing its intellectual property portfolio.

The development aims to incorporate proprietary components into the next-generation vaccine aimed at broadening the immune response, with a goal set for clinical studies to begin around 2027. The current state of affairs indicates that C. difficile infections often occur following antibiotic treatments that disrupt the gut microbiome, causing health complications and leading to high recurrence rates. Despite this significant burden, there is currently no approved prophylactic vaccine available, making this partnership notably relevant.

Thomas Lingelbach, the CEO of Valneva, echoed the collective concern over the public health implications of C. difficile, stating, "CDI continues to pose a significant public health challenge... We are pleased to partner with Elaris to advance this technology."

As Elaris progresses through the various stages of development, the company is poised to make important contributions to reducing hospitalizations and antibiotic use associated with these infections. Elaris is dedicated to shifting the healthcare focus from treating infections to preventing them, thereby addressing the escalating burden of antimicrobial resistance.

The partnership not only involves advancing vaccine development but also includes customary developmental and regulatory milestone payments, along with royalties on future sales. As the project unfolds, the world will be closely observing the evolution of vaccine research, approval processes, and its inevitable impact on global health amidst rising infection threats.

For more details about the groundbreaking work at Elaris, visit their official site at www.elaris.com and stay tuned for updates on their progress in fighting C. difficile infections.